🇺🇸 FDA
Patent

US 8563576

Tri-cyclic pyrazolopyridine kinase inhibitors

granted A61PA61P1/00A61P1/04

Quick answer

US patent 8563576 (Tri-cyclic pyrazolopyridine kinase inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Oct 22 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 17 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P1/00, A61P1/04, A61P11/06, A61P17/02